[1]
Klareskog L, Rönnelid J, Saevarsdottir S, Padyukov L, Alfredsson L. The importance of differences; On environment and its interactions with genes and immunity in the causation of rheumatoid arthritis. Journal of internal medicine. 2020 May:287(5):514-533. doi: 10.1111/joim.13058. Epub
[PubMed PMID: 32176395]
[2]
Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet (London, England). 2016 Oct 22:388(10055):2023-2038. doi: 10.1016/S0140-6736(16)30173-8. Epub 2016 May 3
[PubMed PMID: 27156434]
[3]
Bullock J, Rizvi SAA, Saleh AM, Ahmed SS, Do DP, Ansari RA, Ahmed J. Rheumatoid Arthritis: A Brief Overview of the Treatment. Medical principles and practice : international journal of the Kuwait University, Health Science Centre. 2018:27(6):501-507. doi: 10.1159/000493390. Epub 2018 Sep 2
[PubMed PMID: 30173215]
Level 3 (low-level) evidence
[5]
Pincus T, O'Dell JR, Kremer JM. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Annals of internal medicine. 1999 Nov 16:131(10):768-74
[PubMed PMID: 10577301]
[6]
Silman AJ, MacGregor AJ, Thomson W, Holligan S, Carthy D, Farhan A, Ollier WE. Twin concordance rates for rheumatoid arthritis: results from a nationwide study. British journal of rheumatology. 1993 Oct:32(10):903-7
[PubMed PMID: 8402000]
[7]
Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis and rheumatism. 1987 Nov:30(11):1205-13
[PubMed PMID: 2446635]
Level 3 (low-level) evidence
[8]
Weyand CM,Hicok KC,Conn DL,Goronzy JJ, The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Annals of internal medicine. 1992 Nov 15;
[PubMed PMID: 1416553]
[9]
du Teil Espina M, Gabarrini G, Harmsen HJM, Westra J, van Winkelhoff AJ, van Dijl JM. Talk to your gut: the oral-gut microbiome axis and its immunomodulatory role in the etiology of rheumatoid arthritis. FEMS microbiology reviews. 2019 Jan 1:43(1):1-18. doi: 10.1093/femsre/fuy035. Epub
[PubMed PMID: 30219863]
[10]
Wu H, Liao W, Li Q, Long H, Yin H, Zhao M, Chan V, Lau CS, Lu Q. Pathogenic role of tissue-resident memory T cells in autoimmune diseases. Autoimmunity reviews. 2018 Sep:17(9):906-911. doi: 10.1016/j.autrev.2018.03.014. Epub 2018 Jul 10
[PubMed PMID: 30005862]
[11]
Okada Y, Eyre S, Suzuki A, Kochi Y, Yamamoto K. Genetics of rheumatoid arthritis: 2018 status. Annals of the rheumatic diseases. 2019 Apr:78(4):446-453. doi: 10.1136/annrheumdis-2018-213678. Epub 2018 Dec 8
[PubMed PMID: 30530827]
[12]
Dedmon LE. The genetics of rheumatoid arthritis. Rheumatology (Oxford, England). 2020 Oct 1:59(10):2661-2670. doi: 10.1093/rheumatology/keaa232. Epub
[PubMed PMID: 32638005]
[13]
Padyukov L. Genetics of rheumatoid arthritis. Seminars in immunopathology. 2022 Jan:44(1):47-62. doi: 10.1007/s00281-022-00912-0. Epub 2022 Jan 27
[PubMed PMID: 35088123]
[14]
Ciccacci C,Conigliaro P,Perricone C,Rufini S,Triggianese P,Politi C,Novelli G,Perricone R,Borgiani P, Polymorphisms in STAT-4, IL-10, PSORS1C1, PTPN2 and MIR146A genes are associated differently with prognostic factors in Italian patients affected by rheumatoid arthritis. Clinical and experimental immunology. 2016 Nov
[PubMed PMID: 27342690]
[15]
Stanford SM, Maestre MF, Campbell AM, Bartok B, Kiosses WB, Boyle DL, Arnett HA, Mustelin T, Firestein GS, Bottini N. Protein tyrosine phosphatase expression profile of rheumatoid arthritis fibroblast-like synoviocytes: a novel role of SH2 domain-containing phosphatase 2 as a modulator of invasion and survival. Arthritis and rheumatism. 2013 May:65(5):1171-80. doi: 10.1002/art.37872. Epub
[PubMed PMID: 23335101]
[16]
Stolt P, Bengtsson C, Nordmark B, Lindblad S, Lundberg I, Klareskog L, Alfredsson L, EIRA study group. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Annals of the rheumatic diseases. 2003 Sep:62(9):835-41
[PubMed PMID: 12922955]
Level 2 (mid-level) evidence
[17]
Padyukov L, Silva C, Stolt P, Alfredsson L, Klareskog L. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis and rheumatism. 2004 Oct:50(10):3085-92
[PubMed PMID: 15476204]
[18]
Linn-Rasker SP,van der Helm-van Mil AH,van Gaalen FA,Kloppenburg M,de Vries RR,le Cessie S,Breedveld FC,Toes RE,Huizinga TW, Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Annals of the rheumatic diseases. 2006 Mar;
[PubMed PMID: 16014670]
[19]
Klareskog L, Stolt P, Lundberg K, Källberg H, Bengtsson C, Grunewald J, Rönnelid J, Harris HE, Ulfgren AK, Rantapää-Dahlqvist S, Eklund A, Padyukov L, Alfredsson L. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis and rheumatism. 2006 Jan:54(1):38-46
[PubMed PMID: 16385494]
[20]
Lundström E, Källberg H, Alfredsson L, Klareskog L, Padyukov L. Gene-environment interaction between the DRB1 shared epitope and smoking in the risk of anti-citrullinated protein antibody-positive rheumatoid arthritis: all alleles are important. Arthritis and rheumatism. 2009 Jun:60(6):1597-603. doi: 10.1002/art.24572. Epub
[PubMed PMID: 19479873]
[21]
Sugiyama D, Nishimura K, Tamaki K, Tsuji G, Nakazawa T, Morinobu A, Kumagai S. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Annals of the rheumatic diseases. 2010 Jan:69(1):70-81. doi: 10.1136/ard.2008.096487. Epub
[PubMed PMID: 19174392]
Level 1 (high-level) evidence
[22]
Derksen VFAM,Huizinga TWJ,van der Woude D, The role of autoantibodies in the pathophysiology of rheumatoid arthritis. Seminars in immunopathology. 2017 Jun
[PubMed PMID: 28451788]
[23]
Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, Williams B, Gabriel S, Lassere M, Johns N, Buchbinder R, Woolf A, March L. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Annals of the rheumatic diseases. 2014 Jul:73(7):1316-22. doi: 10.1136/annrheumdis-2013-204627. Epub 2014 Feb 18
[PubMed PMID: 24550173]
[24]
Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. Arthritis and rheumatism. 2010 Jun:62(6):1576-82. doi: 10.1002/art.27425. Epub
[PubMed PMID: 20191579]
[25]
Crowson CS, Matteson EL, Myasoedova E, Michet CJ, Ernste FC, Warrington KJ, Davis JM 3rd, Hunder GG, Therneau TM, Gabriel SE. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis and rheumatism. 2011 Mar:63(3):633-9. doi: 10.1002/art.30155. Epub
[PubMed PMID: 21360492]
[26]
Eriksson JK,Neovius M,Ernestam S,Lindblad S,Simard JF,Askling J, Incidence of rheumatoid arthritis in Sweden: a nationwide population-based assessment of incidence, its determinants, and treatment penetration. Arthritis care & research. 2013 Jun
[PubMed PMID: 23281173]
[27]
Safiri S, Kolahi AA, Hoy D, Smith E, Bettampadi D, Mansournia MA, Almasi-Hashiani A, Ashrafi-Asgarabad A, Moradi-Lakeh M, Qorbani M, Collins G, Woolf AD, March L, Cross M. Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017. Annals of the rheumatic diseases. 2019 Nov:78(11):1463-1471. doi: 10.1136/annrheumdis-2019-215920. Epub 2019 Sep 11
[PubMed PMID: 31511227]
Level 1 (high-level) evidence
[28]
Almutairi KB,Nossent JC,Preen DB,Keen HI,Inderjeeth CA, The Prevalence of Rheumatoid Arthritis: A Systematic Review of Population-based Studies. The Journal of rheumatology. 2021 May;
[PubMed PMID: 33060323]
Level 1 (high-level) evidence
[29]
Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatology international. 2021 May:41(5):863-877. doi: 10.1007/s00296-020-04731-0. Epub 2020 Nov 11
[PubMed PMID: 33175207]
Level 1 (high-level) evidence
[30]
Frisell T, Holmqvist M, Källberg H, Klareskog L, Alfredsson L, Askling J. Familial risks and heritability of rheumatoid arthritis: role of rheumatoid factor/anti-citrullinated protein antibody status, number and type of affected relatives, sex, and age. Arthritis and rheumatism. 2013 Nov:65(11):2773-82. doi: 10.1002/art.38097. Epub
[PubMed PMID: 23897126]
[31]
Philippou E, Nikiphorou E. Are we really what we eat? Nutrition and its role in the onset of rheumatoid arthritis. Autoimmunity reviews. 2018 Nov:17(11):1074-1077. doi: 10.1016/j.autrev.2018.05.009. Epub 2018 Sep 10
[PubMed PMID: 30213695]
[32]
Qin B,Yang M,Fu H,Ma N,Wei T,Tang Q,Hu Z,Liang Y,Yang Z,Zhong R, Body mass index and the risk of rheumatoid arthritis: a systematic review and dose-response meta-analysis. Arthritis research & therapy. 2015 Mar 29
[PubMed PMID: 25890172]
Level 2 (mid-level) evidence
[33]
Li X, Sundquist J, Sundquist K. Socioeconomic and occupational risk factors for rheumatoid arthritis: a nationwide study based on hospitalizations in Sweden. The Journal of rheumatology. 2008 Jun:35(6):986-91
[PubMed PMID: 18464310]
[34]
De Roos AJ, Koehoorn M, Tamburic L, Davies HW, Brauer M. Proximity to traffic, ambient air pollution, and community noise in relation to incident rheumatoid arthritis. Environmental health perspectives. 2014 Oct:122(10):1075-80. doi: 10.1289/ehp.1307413. Epub 2014 Jun 6
[PubMed PMID: 24905961]
Level 3 (low-level) evidence
[35]
NIENHUIS RL, MANDEMA E. A NEW SERUM FACTOR IN PATIENTS WITH RHEUMATOID ARTHRITIS; THE ANTIPERINUCLEAR FACTOR. Annals of the rheumatic diseases. 1964 Jul:23(4):302-5
[PubMed PMID: 14178016]
[36]
Young BJ,Mallya RK,Leslie RD,Clark CJ,Hamblin TJ, Anti-keratin antibodies in rheumatoid arthritis. British medical journal. 1979 Jul 14
[PubMed PMID: 111762]
[37]
Sebbag M, Simon M, Vincent C, Masson-Bessière C, Girbal E, Durieux JJ, Serre G. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. The Journal of clinical investigation. 1995 Jun:95(6):2672-9
[PubMed PMID: 7539459]
[38]
Hoet RM, Boerbooms AM, Arends M, Ruiter DJ, van Venrooij WJ. Antiperinuclear factor, a marker autoantibody for rheumatoid arthritis: colocalisation of the perinuclear factor and profilaggrin. Annals of the rheumatic diseases. 1991 Sep:50(9):611-8
[PubMed PMID: 1718228]
[39]
Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, van Venrooij WJ. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis and rheumatism. 2000 Jan:43(1):155-63
[PubMed PMID: 10643712]
[40]
van Delft MAM,Huizinga TWJ, An overview of autoantibodies in rheumatoid arthritis. Journal of autoimmunity. 2020 Jun
[PubMed PMID: 31911013]
Level 3 (low-level) evidence
[41]
Makrygiannakis D, Hermansson M, Ulfgren AK, Nicholas AP, Zendman AJ, Eklund A, Grunewald J, Skold CM, Klareskog L, Catrina AI. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Annals of the rheumatic diseases. 2008 Oct:67(10):1488-92. doi: 10.1136/ard.2007.075192. Epub 2008 Apr 15
[PubMed PMID: 18413445]
[42]
Curran AM, Naik P, Giles JT, Darrah E. PAD enzymes in rheumatoid arthritis: pathogenic effectors and autoimmune targets. Nature reviews. Rheumatology. 2020 Jun:16(6):301-315. doi: 10.1038/s41584-020-0409-1. Epub 2020 Apr 27
[PubMed PMID: 32341463]
[43]
Gómez-Bañuelos E, Mukherjee A, Darrah E, Andrade F. Rheumatoid Arthritis-Associated Mechanisms of Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans. Journal of clinical medicine. 2019 Aug 26:8(9):. doi: 10.3390/jcm8091309. Epub 2019 Aug 26
[PubMed PMID: 31454946]
[44]
Volkov M,van Schie KA,van der Woude D, Autoantibodies and B Cells: The ABC of rheumatoid arthritis pathophysiology. Immunological reviews. 2020 Mar
[PubMed PMID: 31845355]
[45]
McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet (London, England). 2017 Jun 10:389(10086):2328-2337. doi: 10.1016/S0140-6736(17)31472-1. Epub
[PubMed PMID: 28612747]
[46]
Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, Habibuw MR, Vandenbroucke JP, Dijkmans BA. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis and rheumatism. 2004 Feb:50(2):380-6
[PubMed PMID: 14872479]
[47]
van Steenbergen HW,Huizinga TW,van der Helm-van Mil AH, The preclinical phase of rheumatoid arthritis: what is acknowledged and what needs to be assessed? Arthritis and rheumatism. 2013 Sep;
[PubMed PMID: 23686440]
[48]
Mankia K, Emery P. Preclinical Rheumatoid Arthritis: Progress Toward Prevention. Arthritis & rheumatology (Hoboken, N.J.). 2016 Apr:68(4):779-88. doi: 10.1002/art.39603. Epub
[PubMed PMID: 26814677]
[49]
Wegner N, Lundberg K, Kinloch A, Fisher B, Malmström V, Feldmann M, Venables PJ. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunological reviews. 2010 Jan:233(1):34-54. doi: 10.1111/j.0105-2896.2009.00850.x. Epub
[PubMed PMID: 20192991]
[50]
Fang Q, Zhou C, Nandakumar KS. Molecular and Cellular Pathways Contributing to Joint Damage in Rheumatoid Arthritis. Mediators of inflammation. 2020:2020():3830212. doi: 10.1155/2020/3830212. Epub 2020 Mar 17
[PubMed PMID: 32256192]
[51]
López-Mejías R, Carmona FD, Genre F, Remuzgo-Martínez S, González-Juanatey C, Corrales A, Vicente EF, Pulito-Cueto V, Miranda-Filloy JA, Ramírez Huaranga MA, Blanco R, Robustillo-Villarino M, Rodríguez-Carrio J, Alperi-López M, Alegre-Sancho JJ, Mijares V, Lera-Gómez L, Pérez-Pampín E, González A, Ortega-Castro R, López-Pedrera C, García Vivar ML, Gómez-Arango C, Raya E, Narvaez J, Balsa A, López-Longo FJ, Carreira P, González-Álvaro I, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Ferraz-Amaro I, Gualillo O, Castañeda S, Martín J, Llorca J, González-Gay MA. Identification of a 3'-Untranslated Genetic Variant of RARB Associated With Carotid Intima-Media Thickness in Rheumatoid Arthritis: A Genome-Wide Association Study. Arthritis & rheumatology (Hoboken, N.J.). 2019 Mar:71(3):351-360. doi: 10.1002/art.40734. Epub 2019 Jan 18
[PubMed PMID: 30251476]
[52]
de Hair MJ, van de Sande MG, Ramwadhdoebe TH, Hansson M, Landewé R, van der Leij C, Maas M, Serre G, van Schaardenburg D, Klareskog L, Gerlag DM, van Baarsen LG, Tak PP. Features of the synovium of individuals at risk of developing rheumatoid arthritis: implications for understanding preclinical rheumatoid arthritis. Arthritis & rheumatology (Hoboken, N.J.). 2014 Mar:66(3):513-22. doi: 10.1002/art.38273. Epub
[PubMed PMID: 24574210]
Level 3 (low-level) evidence
[53]
McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. The New England journal of medicine. 2011 Dec 8:365(23):2205-19. doi: 10.1056/NEJMra1004965. Epub
[PubMed PMID: 22150039]
[54]
de Brito Rocha S,Baldo DC,Andrade LEC, Clinical and pathophysiologic relevance of autoantibodies in rheumatoid arthritis. Advances in rheumatology (London, England). 2019 Jan 17;
[PubMed PMID: 30657101]
Level 3 (low-level) evidence
[55]
Weyand CM, Goronzy JJ. The immunology of rheumatoid arthritis. Nature immunology. 2021 Jan:22(1):10-18. doi: 10.1038/s41590-020-00816-x. Epub 2020 Nov 30
[PubMed PMID: 33257900]
[56]
Lin YJ, Anzaghe M, Schülke S. Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis. Cells. 2020 Apr 3:9(4):. doi: 10.3390/cells9040880. Epub 2020 Apr 3
[PubMed PMID: 32260219]
[57]
Kondo N, Kuroda T, Kobayashi D. Cytokine Networks in the Pathogenesis of Rheumatoid Arthritis. International journal of molecular sciences. 2021 Oct 10:22(20):. doi: 10.3390/ijms222010922. Epub 2021 Oct 10
[PubMed PMID: 34681582]
[58]
Lally F,Smith E,Filer A,Stone MA,Shaw JS,Nash GB,Buckley CD,Rainger GE, A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium. Arthritis and rheumatism. 2005 Nov
[PubMed PMID: 16255036]
[59]
Demasi M, Cleland LG, Cook-Johnson RJ, James MJ. Effects of hypoxia on the expression and activity of cyclooxygenase 2 in fibroblast-like synoviocytes: interactions with monocyte-derived soluble mediators. Arthritis and rheumatism. 2004 Aug:50(8):2441-9
[PubMed PMID: 15334456]
[60]
Chua-Aguilera CJ, Möller B, Yawalkar N. Skin Manifestations of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Spondyloarthritides. Clinical reviews in allergy & immunology. 2017 Dec:53(3):371-393. doi: 10.1007/s12016-017-8632-5. Epub
[PubMed PMID: 28752373]
[62]
Koskinen E,Hannonen P,Sokka T, Palindromic rheumatism: longterm outcomes of 60 patients diagnosed in 1967-84. The Journal of rheumatology. 2009 Sep
[PubMed PMID: 19648311]
[63]
Gonzalez-Lopez L, Gamez-Nava JI, Jhangri G, Russell AS, Suarez-Almazor ME. Decreased progression to rheumatoid arthritis or other connective tissue diseases in patients with palindromic rheumatism treated with antimalarials. The Journal of rheumatology. 2000 Jan:27(1):41-6
[PubMed PMID: 10648016]
[64]
Lehtinen JT, Kaarela K, Belt EA, Kautiainen HJ, Kauppi MJ, Lehto MU. Incidence of acromioclavicular joint involvement in rheumatoid arthritis: a 15 year endpoint study. The Journal of rheumatology. 1999 Jun:26(6):1239-41
[PubMed PMID: 10381036]
[65]
Sayah A, English JC 3rd. Rheumatoid arthritis: a review of the cutaneous manifestations. Journal of the American Academy of Dermatology. 2005 Aug:53(2):191-209; quiz 210-2
[PubMed PMID: 16021111]
[66]
Bongartz T,Nannini C,Medina-Velasquez YF,Achenbach SJ,Crowson CS,Ryu JH,Vassallo R,Gabriel SE,Matteson EL, Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis and rheumatism. 2010 Jun;
[PubMed PMID: 20155830]
[67]
Sparks JA, Jin Y, Cho SK, Vine S, Desai R, Doyle TJ, Kim SC. Prevalence, incidence and cause-specific mortality of rheumatoid arthritis-associated interstitial lung disease among older rheumatoid arthritis patients. Rheumatology (Oxford, England). 2021 Aug 2:60(8):3689-3698. doi: 10.1093/rheumatology/keaa836. Epub
[PubMed PMID: 33462611]
[68]
Samhouri BF, Vassallo R, Achenbach SJ, Kronzer VL, Davis JM 3rd, Myasoedova E, Crowson CS. Incidence, Risk Factors, and Mortality of Clinical and Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Population-Based Cohort. Arthritis care & research. 2022 Dec:74(12):2042-2049. doi: 10.1002/acr.24856. Epub 2022 Aug 10
[PubMed PMID: 34995017]
[69]
Correia CS, Briones MR, Guo R, Ostrowski RA. Elevated anti-cyclic citrullinated peptide antibody titer is associated with increased risk for interstitial lung disease. Clinical rheumatology. 2019 Apr:38(4):1201-1206. doi: 10.1007/s10067-018-04421-0. Epub 2019 Jan 15
[PubMed PMID: 30645754]
[70]
Castellanos-Moreira R,Rodriguez-Garcia SC,Cabrera-Villalba S,Gomara MJ,Salvador G,Ruiz-Esquide V,Ramirez J,Inciarte-Mundo J,Morla R,Garcia-Moreno C,Cuervo A,Gómez-Puerta JA,Cañete JD,Haro I,Sanmarti R, Anti-carbamylated protein antibody isotype pattern differs between palindromic rheumatism and rheumatoid arthritis. Therapeutic advances in musculoskeletal disease. 2020;
[PubMed PMID: 33354232]
Level 3 (low-level) evidence
[71]
England BR, Duryee MJ, Roul P, Mahajan TD, Singh N, Poole JA, Ascherman DP, Caplan L, Demoruelle MK, Deane KD, Klassen LW, Thiele GM, Mikuls TR. Malondialdehyde-Acetaldehyde Adducts and Antibody Responses in Rheumatoid Arthritis-Associated Interstitial Lung Disease. Arthritis & rheumatology (Hoboken, N.J.). 2019 Sep:71(9):1483-1493. doi: 10.1002/art.40900. Epub 2019 Jul 22
[PubMed PMID: 30933423]
[72]
Juge PA, Lee JS, Ebstein E, Furukawa H, Dobrinskikh E, Gazal S, Kannengiesser C, Ottaviani S, Oka S, Tohma S, Tsuchiya N, Rojas-Serrano J, González-Pérez MI, Mejía M, Buendía-Roldán I, Falfán-Valencia R, Ambrocio-Ortiz E, Manali E, Papiris SA, Karageorgas T, Boumpas D, Antoniou K, van Moorsel CHM, van der Vis J, de Man YA, Grutters JC, Wang Y, Borie R, Wemeau-Stervinou L, Wallaert B, Flipo RM, Nunes H, Valeyre D, Saidenberg-Kermanac'h N, Boissier MC, Marchand-Adam S, Frazier A, Richette P, Allanore Y, Sibilia J, Dromer C, Richez C, Schaeverbeke T, Lioté H, Thabut G, Nathan N, Amselem S, Soubrier M, Cottin V, Clément A, Deane K, Walts AD, Fingerlin T, Fischer A, Ryu JH, Matteson EL, Niewold TB, Assayag D, Gross A, Wolters P, Schwarz MI, Holers M, Solomon JJ, Doyle T, Rosas IO, Blauwendraat C, Nalls MA, Debray MP, Boileau C, Crestani B, Schwartz DA, Dieudé P. MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. The New England journal of medicine. 2018 Dec 6:379(23):2209-2219. doi: 10.1056/NEJMoa1801562. Epub 2018 Oct 20
[PubMed PMID: 30345907]
[73]
Conforti A, Di Cola I, Pavlych V, Ruscitti P, Berardicurti O, Ursini F, Giacomelli R, Cipriani P. Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. Autoimmunity reviews. 2021 Feb:20(2):102735. doi: 10.1016/j.autrev.2020.102735. Epub 2020 Dec 17
[PubMed PMID: 33346115]
[74]
Abdulqader Y, Al-Ani M, Parperis K. Rheumatoid vasculitis: early presentation of rheumatoid arthritis. BMJ case reports. 2016 Nov 8:2016():. doi: 10.1136/bcr-2016-217557. Epub 2016 Nov 8
[PubMed PMID: 27873751]
Level 3 (low-level) evidence
[75]
Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, Saigo K, Morinobu A, Koshiba M, Kuntz KM, Kamae I, Kumagai S. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Annals of internal medicine. 2007 Jun 5:146(11):797-808
[PubMed PMID: 17548411]
Level 1 (high-level) evidence
[76]
Rantapää-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis and rheumatism. 2003 Oct:48(10):2741-9
[PubMed PMID: 14558078]
[77]
van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, Toes RE, Huizinga TW. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis and rheumatism. 2004 Mar:50(3):709-15
[PubMed PMID: 15022309]
[78]
Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Annals of the rheumatic diseases. 2006 Jul:65(7):845-51
[PubMed PMID: 16606649]
Level 1 (high-level) evidence
[79]
Ramos-Remus C,Castillo-Ortiz JD,Aguilar-Lozano L,Padilla-Ibarra J,Sandoval-Castro C,Vargas-Serafin CO,de la Mora-Molina H,Ramos-Gomez A,Sanchez-Ortiz A,Avila-Armengol H,Aceves-Avila FJ, Autoantibodies in prediction of the development of rheumatoid arthritis among healthy relatives of patients with the disease. Arthritis & rheumatology (Hoboken, N.J.). 2015 Nov
[PubMed PMID: 26245885]
[80]
Bemis EA, Demoruelle MK, Seifert JA, Polinski KJ, Weisman MH, Buckner JH, Gregersen PK, Mikuls TR, ODell JR, Keating RM, Deane KD, Holers VM, Norris JM. Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting. Annals of the rheumatic diseases. 2021 Feb:80(2):154-161. doi: 10.1136/annrheumdis-2020-217066. Epub 2020 Sep 14
[PubMed PMID: 32928740]
[81]
Kortekangas P, Aro HT, Tuominen J, Toivanen A. Synovial fluid leukocytosis in bacterial arthritis vs. reactive arthritis and rheumatoid arthritis in the adult knee. Scandinavian journal of rheumatology. 1992:21(6):283-8
[PubMed PMID: 1475638]
[82]
Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. The Journal of rheumatology. 1989 May:16(5):585-91
[PubMed PMID: 2754663]
[84]
McQueen FM, Stewart N, Crabbe J, Robinson E, Yeoman S, Tan PL, McLean L. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals progression of erosions despite clinical improvement. Annals of the rheumatic diseases. 1999 Mar:58(3):156-63
[PubMed PMID: 10364913]
[85]
Cornec D, Varache S, Morvan J, Devauchelle-Pensec V, Berthelot JM, Le Henaff-Bourhis C, Hoang S, Martin A, Chalès G, Jousse-Joulin S, Saraux A. Comparison of ACR 1987 and ACR/EULAR 2010 criteria for predicting a 10-year diagnosis of rheumatoid arthritis. Joint bone spine. 2012 Dec:79(6):581-5. doi: 10.1016/j.jbspin.2012.01.015. Epub 2012 Mar 9
[PubMed PMID: 22405855]
[86]
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis and rheumatism. 2010 Sep:62(9):2569-81. doi: 10.1002/art.27584. Epub
[PubMed PMID: 20872595]
[87]
Smolen JS,Breedveld FC,Burmester GR,Bykerk V,Dougados M,Emery P,Kvien TK,Navarro-Compán MV,Oliver S,Schoels M,Scholte-Voshaar M,Stamm T,Stoffer M,Takeuchi T,Aletaha D,Andreu JL,Aringer M,Bergman M,Betteridge N,Bijlsma H,Burkhardt H,Cardiel M,Combe B,Durez P,Fonseca JE,Gibofsky A,Gomez-Reino JJ,Graninger W,Hannonen P,Haraoui B,Kouloumas M,Landewe R,Martin-Mola E,Nash P,Ostergaard M,Östör A,Richards P,Sokka-Isler T,Thorne C,Tzioufas AG,van Vollenhoven R,de Wit M,van der Heijde D, Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Annals of the rheumatic diseases. 2016 Jan;
[PubMed PMID: 25969430]
[88]
Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, Saag KG, O'Dell JR, Kazi S. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis care & research. 2012 May:64(5):640-7. doi: 10.1002/acr.21649. Epub
[PubMed PMID: 22473918]
[89]
England BR, Tiong BK, Bergman MJ, Curtis JR, Kazi S, Mikuls TR, O'Dell JR, Ranganath VK, Limanni A, Suter LG, Michaud K. 2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures. Arthritis care & research. 2019 Dec:71(12):1540-1555. doi: 10.1002/acr.24042. Epub 2019 Nov 11
[PubMed PMID: 31709779]
[90]
Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis & rheumatology (Hoboken, N.J.). 2016 Jan:68(1):1-26. doi: 10.1002/art.39480. Epub 2015 Nov 6
[PubMed PMID: 26545940]
[91]
Solomon DH,Husni ME,Wolski KE,Wisniewski LM,Borer JS,Graham DY,Libby P,Lincoff AM,Lüscher TF,Menon V,Yeomans ND,Wang Q,Bao W,Berger MF,Nissen SE,PRECISION Trial Investigators., Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial. Arthritis & rheumatology (Hoboken, N.J.). 2018 Apr
[PubMed PMID: 29266879]
Level 1 (high-level) evidence
[92]
Solomon DH, Husni ME, Libby PA, Yeomans ND, Lincoff AM, Lϋscher TF, Menon V, Brennan DM, Wisniewski LM, Nissen SE, Borer JS. The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial. The American journal of medicine. 2017 Dec:130(12):1415-1422.e4. doi: 10.1016/j.amjmed.2017.06.028. Epub 2017 Jul 26
[PubMed PMID: 28756267]
[93]
Burmester G, Lanas A, Biasucci L, Hermann M, Lohmander S, Olivieri I, Scarpignato C, Smolen J, Hawkey C, Bajkowski A, Berenbaum F, Breedveld F, Dieleman P, Dougados M, MacDonald T, Mola EM, Mets T, Van den Noortgate N, Stoevelaar H. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Annals of the rheumatic diseases. 2011 May:70(5):818-22. doi: 10.1136/ard.2010.128660. Epub 2010 Sep 10
[PubMed PMID: 20833736]
Level 3 (low-level) evidence
[94]
Ashworth NL,Peloso PM,Muhajarine N,Stang M, A population based historical cohort study of the mortality associated with nabumetone, Arthrotec, diclofenac, and naproxen. The Journal of rheumatology. 2004 May;
[PubMed PMID: 15124256]
[95]
van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Annals of internal medicine. 2002 Jan 1:136(1):1-12
[PubMed PMID: 11777359]
Level 1 (high-level) evidence
[96]
Bakker MF,Jacobs JW,Welsing PM,Verstappen SM,Tekstra J,Ton E,Geurts MA,van der Werf JH,van Albada-Kuipers GA,Jahangier-de Veen ZN,van der Veen MJ,Verhoef CM,Lafeber FP,Bijlsma JW,Utrecht Rheumatoid Arthritis Cohort Study Group., Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Annals of internal medicine. 2012 Mar 6
[PubMed PMID: 22393128]
Level 1 (high-level) evidence
[97]
Krause D, Mai A, Klaassen-Mielke R, Timmesfeld N, Trampisch U, Rudolf H, Baraliakos X, Schmitz E, Fendler C, Klink C, Boeddeker S, Saracbasi-Zender E, Christoph HJ, Igelmann M, Menne HJ, Schmid A, Rau R, Wassenberg S, Sonuc N, Ose C, Schade-Brittinger C, Trampisch HJ, Braun J. The Efficacy of Short-Term Bridging Strategies With High- and Low-Dose Prednisolone on Radiographic and Clinical Outcomes in Active Early Rheumatoid Arthritis: A Double-Blind, Randomized, Placebo-Controlled Trial. Arthritis & rheumatology (Hoboken, N.J.). 2022 Oct:74(10):1628-1637. doi: 10.1002/art.42245. Epub
[PubMed PMID: 35643951]
Level 2 (mid-level) evidence
[98]
Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Annals of the rheumatic diseases. 2009 Jul:68(7):1094-9. doi: 10.1136/ard.2008.092668. Epub 2008 Nov 25
[PubMed PMID: 19033290]
Level 1 (high-level) evidence
[99]
Braun J,Kästner P,Flaxenberg P,Währisch J,Hanke P,Demary W,von Hinüber U,Rockwitz K,Heitz W,Pichlmeier U,Guimbal-Schmolck C,Brandt A,MC-MTX.6/RH Study Group., Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis and rheumatism. 2008 Jan;
[PubMed PMID: 18163521]
Level 1 (high-level) evidence
[100]
Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M. Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis. The Journal of rheumatology. 2006 Mar:33(3):481-5
[PubMed PMID: 16463431]
[101]
O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, Fernandez A, Blakely K, Wees S, Stoner J, Hadley S, Felt J, Palmer W, Waytz P, Churchill M, Klassen L, Moore G. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis and rheumatism. 2002 May:46(5):1164-70
[PubMed PMID: 12115219]
Level 1 (high-level) evidence
[102]
O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, Lew RA, Cannella AC, Kunkel G, Phibbs CS, Anis AH, Leatherman S, Keystone E, CSP 551 RACAT Investigators. Therapies for active rheumatoid arthritis after methotrexate failure. The New England journal of medicine. 2013 Jul 25:369(4):307-18. doi: 10.1056/NEJMoa1303006. Epub 2013 Jun 11
[PubMed PMID: 23755969]
[103]
Sauer BC,Teng CC,Tang D,Leng J,Curtis JR,Mikuls TR,Harrison DJ,Cannon GW, Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis. Arthritis care & research. 2017 Mar
[PubMed PMID: 27273801]
[104]
Erhardt DP, Cannon GW, Teng CC, Mikuls TR, Curtis JR, Sauer BC. Low Persistence Rates in Patients With Rheumatoid Arthritis Treated With Triple Therapy and Adverse Drug Events Associated With Sulfasalazine. Arthritis care & research. 2019 Oct:71(10):1326-1335. doi: 10.1002/acr.23759. Epub 2019 Aug 30
[PubMed PMID: 30221485]
[105]
Curtis JR, Palmer JL, Reed GW, Greenberg J, Pappas DA, Harrold LR, Kremer JM. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis. Arthritis care & research. 2021 Aug:73(8):1114-1124. doi: 10.1002/acr.24253. Epub
[PubMed PMID: 32374918]
[106]
Karlsson JA, Neovius M, Nilsson JÅ, Petersson IF, Bratt J, van Vollenhoven RF, Ernestam S, Geborek P. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial. Annals of the rheumatic diseases. 2013 Dec:72(12):1927-33. doi: 10.1136/annrheumdis-2012-202062. Epub 2012 Nov 29
[PubMed PMID: 23196701]
Level 2 (mid-level) evidence
[107]
Garcês S,Demengeot J,Benito-Garcia E, The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Annals of the rheumatic diseases. 2013 Dec;
[PubMed PMID: 23223420]
Level 1 (high-level) evidence
[108]
Porter D, van Melckebeke J, Dale J, Messow CM, McConnachie A, Walker A, Munro R, McLaren J, McRorie E, Packham J, Buckley CD, Harvie J, Taylor P, Choy E, Pitzalis C, McInnes IB. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet (London, England). 2016 Jul 16:388(10041):239-47. doi: 10.1016/S0140-6736(16)00380-9. Epub 2016 May 17
[PubMed PMID: 27197690]
Level 1 (high-level) evidence
[109]
Genovese MC, Pacheco-Tena C, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente RM, Nash P, Simon-Campos JA, Box J, Legerton CW 3rd, Nasonov E, Durez P, Elegbe A, Wong R, Li X, Banerjee S, Alten R. Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial. The Journal of rheumatology. 2018 Aug:45(8):1085-1092. doi: 10.3899/jrheum.170344. Epub 2018 Apr 15
[PubMed PMID: 29657147]
[110]
Smolen JS, Schoels MM, Nishimoto N, Breedveld FC, Burmester GR, Dougados M, Emery P, Ferraccioli G, Gabay C, Gibofsky A, Gomez-Reino JJ, Jones G, Kvien TK, Murakami M, Betteridge N, Bingham CO 3rd, Bykerk V, Choy EH, Combe B, Cutolo M, Graninger W, Lanas A, Martin-Mola E, Montecucco C, Ostergaard M, Pavelka K, Rubbert-Roth A, Sattar N, Scholte-Voshaar M, Tanaka Y, Trauner M, Valentini G, Winthrop KL, de Wit M, van der Heijde D. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Annals of the rheumatic diseases. 2013 Apr:72(4):482-92. doi: 10.1136/annrheumdis-2012-202469. Epub 2012 Nov 21
[PubMed PMID: 23172750]
Level 3 (low-level) evidence
[111]
Fleischmann R,van Adelsberg J,Lin Y,Castelar-Pinheiro GD,Brzezicki J,Hrycaj P,Graham NM,van Hoogstraten H,Bauer D,Burmester GR, Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. Arthritis & rheumatology (Hoboken, N.J.). 2017 Feb
[PubMed PMID: 27860410]
[112]
Wallenstein GV, Kanik KS, Wilkinson B, Cohen S, Cutolo M, Fleischmann RM, Genovese MC, Gomez Reino J, Gruben D, Kremer J, Krishnaswami S, Lee EB, Pascual-Ramos V, Strand V, Zwillich SH. Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials. Clinical and experimental rheumatology. 2016 May-Jun:34(3):430-42
[PubMed PMID: 27156561]
Level 1 (high-level) evidence
[113]
Gwinnutt JM, Symmons DPM, MacGregor AJ, Chipping JR, Marshall T, Lunt M, Verstappen SMM. Twenty-Year Outcome and Association Between Early Treatment and Mortality and Disability in an Inception Cohort of Patients With Rheumatoid Arthritis: Results From the Norfolk Arthritis Register. Arthritis & rheumatology (Hoboken, N.J.). 2017 Aug:69(8):1566-1575. doi: 10.1002/art.40090. Epub 2017 Jul 10
[PubMed PMID: 28425173]
[114]
Paul BJ, Kandy HI, Krishnan V. Pre-rheumatoid arthritis and its prevention. European journal of rheumatology. 2017 Jun:4(2):161-165. doi: 10.5152/eurjrheum.2017.16006. Epub 2017 Apr 11
[PubMed PMID: 28638695]
[115]
Holmqvist M, Mantel Ä, Wållberg-Jonsson S, James S, Jernberg T, Askling J. Findings on Coronary Angiographies in Patients With Rheumatoid Arthritis and Ischemic Heart Disease: Are They Different From Patients Without Rheumatoid Arthritis? Arthritis care & research. 2021 May:73(5):658-665. doi: 10.1002/acr.24214. Epub
[PubMed PMID: 33285616]
[116]
Solomon DH, Goodson NJ, Katz JN, Weinblatt ME, Avorn J, Setoguchi S, Canning C, Schneeweiss S. Patterns of cardiovascular risk in rheumatoid arthritis. Annals of the rheumatic diseases. 2006 Dec:65(12):1608-12
[PubMed PMID: 16793844]
[117]
Martin-Trujillo A,van Rietschoten JG,Timmer TC,Rodríguez FM,Huizinga TW,Tak PP,Marsal S,Ibrahim SM,Dijkmans BA,van der Pouw Kraan TC,Verweij CL, Loss of imprinting of IGF2 characterises high IGF2 mRNA-expressing type of fibroblast-like synoviocytes in rheumatoid arthritis. Annals of the rheumatic diseases. 2010 Jun;
[PubMed PMID: 19556211]
[118]
Atzeni F, Masala IF, di Franco M, Sarzi-Puttini P. Infections in rheumatoid arthritis. Current opinion in rheumatology. 2017 Jul:29(4):323-330. doi: 10.1097/BOR.0000000000000389. Epub
[PubMed PMID: 28422773]
Level 3 (low-level) evidence
[119]
Carbone F, Bonaventura A, Liberale L, Paolino S, Torre F, Dallegri F, Montecucco F, Cutolo M. Atherosclerosis in Rheumatoid Arthritis: Promoters and Opponents. Clinical reviews in allergy & immunology. 2020 Feb:58(1):1-14. doi: 10.1007/s12016-018-8714-z. Epub
[PubMed PMID: 30259381]
[120]
Nicolau J, Lequerré T, Bacquet H, Vittecoq O. Rheumatoid arthritis, insulin resistance, and diabetes. Joint bone spine. 2017 Jul:84(4):411-416. doi: 10.1016/j.jbspin.2016.09.001. Epub 2016 Oct 21
[PubMed PMID: 27777170]
[121]
Naranjo A,Sokka T,Descalzo MA,Calvo-Alén J,Hørslev-Petersen K,Luukkainen RK,Combe B,Burmester GR,Devlin J,Ferraccioli G,Morelli A,Hoekstra M,Majdan M,Sadkiewicz S,Belmonte M,Holmqvist AC,Choy E,Tunc R,Dimic A,Bergman M,Toloza S,Pincus T,QUEST-RA Group., Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis research & therapy. 2008
[PubMed PMID: 18325087]
[122]
Ozen G, Pedro S, Michaud K. The Risk of Cardiovascular Events Associated With Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. The Journal of rheumatology. 2021 May:48(5):648-655. doi: 10.3899/jrheum.200265. Epub 2020 Aug 15
[PubMed PMID: 32801134]
[123]
Xie F, Chen L, Yun H, Levitan EB, Curtis JR. Benefits of Methotrexate Use on Cardiovascular Disease Risk Among Rheumatoid Arthritis Patients Initiating Biologic Disease-modifying Antirheumatic Drugs. The Journal of rheumatology. 2021 Jun:48(6):804-812. doi: 10.3899/jrheum.191326. Epub 2020 Oct 15
[PubMed PMID: 33060309]
[124]
Klein A, Polliack A, Gafter-Gvili A. Rheumatoid arthritis and lymphoma: Incidence, pathogenesis, biology, and outcome. Hematological oncology. 2018 Dec:36(5):733-739. doi: 10.1002/hon.2525. Epub 2018 Jun 3
[PubMed PMID: 29862535]
[125]
Baecklund E,Iliadou A,Askling J,Ekbom A,Backlin C,Granath F,Catrina AI,Rosenquist R,Feltelius N,Sundström C,Klareskog L, Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis and rheumatism. 2006 Mar
[PubMed PMID: 16508929]
[126]
Hellgren K, Baecklund E, Backlin C, Sundstrom C, Smedby KE, Askling J. Rheumatoid Arthritis and Risk of Malignant Lymphoma: Is the Risk Still Increased? Arthritis & rheumatology (Hoboken, N.J.). 2017 Apr:69(4):700-708. doi: 10.1002/art.40017. Epub
[PubMed PMID: 27992692]
[127]
Jin S, Hsieh E, Peng L, Yu C, Wang Y, Wu C, Wang Q, Li M, Zeng X. Incidence of fractures among patients with rheumatoid arthritis: a systematic review and meta-analysis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2018 Jun:29(6):1263-1275. doi: 10.1007/s00198-018-4473-1. Epub 2018 Mar 15
[PubMed PMID: 29546507]
Level 1 (high-level) evidence
[128]
Kim SC, Schneeweiss S, Liu J, Solomon DH. Risk of venous thromboembolism in patients with rheumatoid arthritis. Arthritis care & research. 2013 Oct:65(10):1600-7. doi: 10.1002/acr.22039. Epub
[PubMed PMID: 23666917]
[129]
Bacani AK,Gabriel SE,Crowson CS,Heit JA,Matteson EL, Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events? Arthritis and rheumatism. 2012 Jan
[PubMed PMID: 21905005]
[130]
Liang H, Danwada R, Guo D, Curtis JR, Kilpatrick RD, Hendrickson B, Islam SS. Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting. RMD open. 2019:5(2):e001013. doi: 10.1136/rmdopen-2019-001013. Epub 2019 Sep 23
[PubMed PMID: 31673413]
[131]
Matcham F, Rayner L, Steer S, Hotopf M. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford, England). 2013 Dec:52(12):2136-48. doi: 10.1093/rheumatology/ket169. Epub 2013 Sep 3
[PubMed PMID: 24003249]
Level 1 (high-level) evidence
[132]
Muñoz-Fernández S, Otón-Sánchez T, Carmona L, Calvo-Alén J, Escudero A, Narváez J, Rodríguez Heredia JM, Romero Yuste S, Vela P, Luján Valdés S, Royo García A, Baquero JL. Use of prognostic factors of rheumatoid arthritis in clinical practice and perception of their predictive capacity before and after exposure to evidence. Rheumatology international. 2018 Dec:38(12):2289-2296. doi: 10.1007/s00296-018-4152-8. Epub 2018 Sep 24
[PubMed PMID: 30251128]
[133]
Solomon DH,Yu Z,Katz JN,Bitton A,Corrigan C,Fraenkel L,Harrold LR,Smolen JS,Losina E,Lu B, Adverse Events and Resource Use Before and After Treat-to-Target in Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial. Arthritis care & research. 2019 Sep
[PubMed PMID: 30221841]
Level 1 (high-level) evidence